Edgewise Therapeutics, Inc. Price/Book Ratio
The price-to-book (P/B) ratio compares what the stock market says a company is worth with what the company's own books say it is worth. It is market capitalization divided by shareholder equity, the book value left after subtracting liabilities from assets, and the table shows both amounts. A ratio of 1.0 means market value equals book value; a higher ratio means investors value the company above its net assets, often for brands, software or expected growth the books do not record. A negative ratio means equity is negative. Each point uses the filed share count and the last closing price on or before the equity's reporting date, never today's price.
- Edgewise Therapeutics, Inc. price/book ratio for the quarter ending 2026-06-30 was 9.78, a 317.47% increase year-over-year.
- Edgewise Therapeutics, Inc. price/book ratio for the quarter ending 2026-03-31 was 6.86, a 40.75% increase year-over-year.
- Edgewise Therapeutics, Inc. price/book ratio for the quarter ending 2025-12-31 was 5.05, a 8.48% decline year-over-year.
- Edgewise Therapeutics, Inc. price/book ratio for the quarter ending 2025-09-30 was 3.07, a 40.46% decline year-over-year.
- Edgewise Therapeutics, Inc. price/book ratio for fiscal 2026 was 9.78.
- Edgewise Therapeutics, Inc. price/book ratio for fiscal 2025 was 5.05, a 8.48% decline from fiscal 2024.
- Edgewise Therapeutics, Inc. price/book ratio for fiscal 2024 was 5.51, a 128.10% increase from fiscal 2023.
- Edgewise Therapeutics, Inc. price/book ratio for fiscal 2023 was 2.42, a 48.21% increase from fiscal 2022.
- Available history
- 2021-03-31 to 2026-06-30
- Data captured
Historical Price/Book Ratio
Annual Price/Book Ratio
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 |